Status:
NOT_YET_RECRUITING
A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors
Lead Sponsor:
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Conditions:
Advanced Solid Tumors
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
This is a Phase 1, open-label, dose-escalation and cohort expansion study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IMM2510(Anti-PD-L1 and ...
Eligibility Criteria
Inclusion
- Participant has provided informed consent prior to initiation of any study specific activities/procedures.
- Age greater than or equal to 18 years old at the same time of signing the informed consent.
- Histologically or cytologically confirmed for Solid Tumor.
- Eastern Cooperative Oncology Group (ECOG) 0 to 1.
- Adequate organ function as defined in protocol.
Exclusion
- History of other malignancy within the past 5 years with exceptions.
- Systemic chemotherapy was administered within 3 weeks prior to the first administration.
- Activated symptomatic brain metastases and leptomeningeal disease.
- History of inflammatory bowel disease.
- Participants with symptoms and/or clinical signs and/or uncontrolled active systemic infection within 14 days prior to the first dose of study treatment.
- Participant has known active infection requiring parenteral antibiotic treatment.
Key Trial Info
Start Date :
October 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2029
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT07170787
Start Date
October 15 2025
End Date
July 1 2029
Last Update
September 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Gobroad Cancer Hospital China Pharmaceutical University
Shanghai, Shanghai Municipality, China